Bina Desai

12PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 29, 2026
Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies.

|May 22, 2026
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexity.

|Dec 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.

Qianqian Hu, Lily L Remsing Rix, Bina Desai

|Oct 30, 2025
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.

Hitendra S Solanki, Harshit Shah, Denis Imbody

|Sep 26, 2025
Evolutionary antifragile therapy.

Jeffrey West, Bina Desai, Maximilian Strobl

|Jan 21, 2025
In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer.

Ryoji Kato, Hitendra S Solanki, Hilal Ozakinci

Pageof 2

Frequent Collaborators

9 joint publications

Andriy Marusyk

7 joint publications

Daria Miroshnychenko

5 joint publications

Eric Haura

4 joint publications

Uwe Rix